NCT07226557进行中（未招募）不适用
Cefiderocol vs Best Available Therapy for Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex Infections: A Target Trial Emulation
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 5,000
- 试验地点
- 1
- 主要终点
- Mortality
研究概览
简要总结
This study aims to compare 28-day mortality among patients with carbapenem resistant A. baumannii infections in two hypothetical target trials where patients receive 7 days of a cefiderocol-based treatment strategy or 7 days of a best available therapy treatment strategy.
详细描述
please see uploaded study protocol
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 100 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Hospitalized adults (≥ 18 years of age)
- •Carbapenem resistant A. baumannii-calcoaceticus complex clinical culture
- •Antimicrobial agent with possible in vitro activity against carbapenem resistant A. baumannii-calcoaceticus complex initiated in the time frame of 2 days before culture collection until 2 days following first available antibiotic susceptibility test result being made available
排除标准
- •Patients with no antibiotic susceptibility testing
- •Patients with only A. baumannii infection diagnosed by rapid diagnostic tests (i.e., multiplex polymerase chain reaction)
- •Initiation of antimicrobial agent outside of selected time frame (i.e., 2 days before culture collection until 2 days after first available antibiotic susceptibility test result was made available)
结局指标
主要结局
Mortality
时间窗: During inpatient admission
In hospital mortality or discharge to hospice during the hospital stay
次要结局
- Length of Stay(Inpatient admission)
- Recurrent CRAB Infection(Within 30 days post discharge)
- Development of antibiotic resistance to initial antibiotic treatment(Subsequent admissions)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Cefepime vs. Carbapenems for Treating AmpC β-lactamase-producing Enterobacteriaceae Bloodstream InfectionsBacteremiaNCT05535751University Hospital, Strasbourg, France200
尚未招募
4 期
comparison of newer and higher dose antibiotics combination therapy with old and standard antibiotics combination therapy in critically ill patients who are carbapenem resistant enterobacteriaceae (CRE)CTRI/2022/09/045736Department of Anaesthesiology and Critical and Care Jawaharlal Nehru Medical College AMU Aligarh80
Unknown
不适用
Clinical Efficacy of Combination Therapy Based on High-dose Biapenem in CRKP InfectionsHigh-dose BiapenemNCT04552444Second Affiliated Hospital, School of Medicine, Zhejiang University200
Unknown
不适用
Comparison of Bloodstream Infections With Carbapenem Hetero-resistant vs Carbapenem Resistant Klebsiella PneumoniaeBloodstream InfectionNCT04229498SCARE (Study group for carbapenem resistance)300
已完成
3 期
A Study Comparing Ceftazidime-Avibactam Versus Meropenem in Hospitalized Adults With Nosocomial PneumoniaNosocomial Pneumonia (NP)Ventilator-associated Pneumonia (VAP)NCT01808092Pfizer969